| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 153, Issue 8 3440-3449, Copyright © 1994 by American Association of Immunologists
ARTICLES |
S Katoh, JB McCarthy and PW Kincade
Oklahoma Medical Research Foundation, Oklahoma City 73104.
ELISA determinations revealed substantial concentrations (0.49 to 2.10 micrograms/ml) of soluble CD44 in murine serum, with some variation among normal mouse strains. At least three species of CD44 were identified by immunoprecipitation and SDS-PAGE analysis of serum. The most prominent was indistinguishable in mobility from that extracted from normal and transformed lymphocytes and was estimated in this way to be approximately 90 kDa. A similar estimate resulted from gel filtration under nondenaturing conditions, followed by ELISA. However, lymphocyte membrane-extracted and soluble CD44 had different mobilities after treatment with neuraminidase plus O-glycosidase, and the core protein of soluble CD44 might be 17 to 20 kDa smaller than that of CD44 on lymphocyte membranes. Furthermore, an Ab to cytoplasmic residues of CD44 failed to recognize soluble CD44 recovered from the circulation or in lymphoma culture supernatants. These observations would be consistent with cleavage of CD44 from cell surfaces; and protease inhibitors slowed the loss of CD44 from cultured lymphomas. Serum CD44 levels were significantly reduced in immunodeficient CD17.SCID and BALB/c.Xid mice, and elevated in tumor-bearing mice. Mild graft-vs-host (GVH) reactions also resulted in increased concentrations of CD44, as did autoimmune disease in BXSB and MRL/lpr strains of mice. Serum with high concentrations of CD44 partially blocked the binding of one ligand, hyaluronate, to CD44-bearing hybridoma cells. The degree of inhibition was positively correlated with CD44 concentration. These findings indicate that substantial quantities of CD44 can be released into the circulation by cleavage from cell surfaces and that this process is markedly influenced by immune system activity and tumor growth. The material seemed to be intact and potentially functional.
This article has been cited by other articles:
|
|
 |
|
  K. J. Garton, P. J. Gough, and E. W. Raines Emerging roles for ectodomain shedding in the regulation of inflammatory responses J. Leukoc. Biol., June 1, 2006; 79(6): 1105 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. A. Rouschop, J. J. T. H. Roelofs, A. T. Rowshani, J. C. Leemans, T. van der Poll, I. J. M. ten Berge, J. J. Weening, and S. Florquin Pre-transplant plasma and cellular levels of CD44 correlate with acute renal allograft rejection Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2248 - 2254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cichy and E. Pure The liberation of CD44 J. Cell Biol., June 9, 2003; 161(5): 839 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cichy, R. Bals, J. Potempa, A. Mani, and E. Pure Proteinase-mediated Release of Epithelial Cell-associated CD44. EXTRACELLULAR CD44 COMPLEXES WITH COMPONENTS OF CELLULAR MATRICES J. Biol. Chem., November 8, 2002; 277(46): 44440 - 44447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Elhabazi, S. Delaire, A. Bensussan, L. Boumsell, and G. Bismuth Biological Activity of Soluble CD100. I. The Extracellular Region of CD100 Is Released from the Surface of T Lymphocytes by Regulated Proteolysis J. Immunol., April 1, 2001; 166(7): 4341 - 4347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fujimoto, H. Kawashima, T. Tanaka, M. Hirose, N. Toyama-Sorimachi, Y. Matsuzawa, and M. Miyasaka CD44 binds a chondroitin sulfate proteoglycan, aggrecan Int. Immunol., March 1, 2001; 13(3): 359 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Martegani, F. Del Prete, A. Gasbarri, P. G. Natali, and A. Bartolazzi Structural Variability of CD44v Molecules and Reliability of Immunodetection of CD44 Isoforms Using mAbs Specific for CD44 Variant Exon Products Am. J. Pathol., January 1, 1999; 154(1): 291 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Yu, B. P. Toole, and I. Stamenkovic Induction of Apoptosis of Metastatic Mammary Carcinoma Cells In Vivo by Disruption of Tumor Cell Surface CD44 Function J. Exp. Med., December 15, 1997; 186(12): 1985 - 1996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ristamaki, H. Joensuu, K. Lappalainen, L. Teerenhovi, and S. Jalkanen Elevated Serum CD44 Level Is Associated With Unfavorable Outcome in Non-Hodgkin's Lymphoma Blood, November 15, 1997; 90(10): 4039 - 4045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rafi, M. Nagarkatti, and P. S. Nagarkatti Hyaluronate-CD44 Interactions Can Induce Murine B-Cell Activation Blood, April 15, 1997; 89(8): 2901 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Yu and B. P. Toole A New Alternatively Spliced Exon between v9 and v10 Provides a Molecular Basis for Synthesis of Soluble CD44 J. Biol. Chem., August 23, 1996; 271(34): 20603 - 20607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Goebeler, D Kaufmann, E. Brocker, and C. Klein Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors J. Cell Sci., January 7, 1996; 109(7): 1957 - 1964. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
